Table 1.
Patient characteristics at baseline by treatment strategy (n = 1,373)
| Met/Incr | Met/SU | p-value vs. Met/Incr | Insulin ± any OAD | p-value vs. Met/Incr | |
|---|---|---|---|---|---|
| (n = 783) | (n = 324) | (n = 266) | |||
| Age (years) | 64.0 (56.7–72.0) | 67.5 (58.2–72.8) | 0.026 | 62.6 (54.5–71.5) | 0.074 |
| Female gender (%) | 47.6 | 46.9 | 0.83 | 42.1 | 0.12 |
| Body weight (kg) | 90.0 (79.0–103.0) | 86.0 (78.0–98.5) | 0.029 | 89.0 (78.0–100.0) | 0.99 |
| Diabetes duration (years) | 4.6 (2.1–7.8) | 5.2 (2.5–8.6) | 0.079 | 6.6 (3.5–9.9) | <0.001 |
| Blood glucose | |||||
| HbA1c (%) | 7.3 (6.8–7.9) | 7.3 (6.8–8.1) | 0.75 | 8.1 (7.3–9.5) | <0.001 |
| FPG (mg/dl) | 137 (118–164) | 139 (117–162) | 0.91 | 156 (132–205) | <0.001 |
| PPG (mg/dl) | 176 (147–211) | 178 (158–215) | 0.13 | 205 (174–241) | <0.001 |
| Anamnestic hypoglycaemia* (%) | 3.4 | 5.2 | 0.16 | 23.3 | <0.001 |
| Concomitant disease (%) | |||||
| MACCE (%) | 9.4 | 11.2 | 0.37 | 10.6 | 0.57 |
| Macrovascular complication (%) | 13.4 | 13.9 | 0.80 | 16.6 | 0.19 |
| Microvascular complication (%) | 14.7 | 12.4 | 0.31 | 22.9 | 0.002 |
Legend: Met/Incr, metformin/incretin; Met/SU, metformin/sulfonylurea; OAD, oral antidiabetic drug; HbA1c, glycosylated haemoglobin A1c, FPG, fasting plasma glucose; PPG, postprandial plasma glucose; MACCE, major cardiac or cerebrovascular event; *within 12 months prior to baseline.